Targeting androgen receptor signaling to enhance cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Urology

Background:

• Men exhibit higher cancer incidence and mortality rates compared to women.
• Androgen receptor (AR) signaling is implicated as a driver of sex-based disparities in cancer.
• AR signaling can suppress the body's adaptive anticancer immune response.

Purpose of the Study:

• To discuss recent developments in understanding AR signaling and anticancer immunity.
• To summarize studies defining the role of AR signaling in immune response to cancer.
• To propose strategies for integrating AR suppression with immunotherapy in clinical trials.

Main Methods:

• Review of preclinical studies on AR inhibition and immune response.
• Analysis of recent Phase 3 clinical trials combining AR suppression and immune checkpoint blockade in prostate cancer.
• Synthesis of current research on AR signaling's role in anticancer immunity.

Main Results:

• Preclinical data suggest AR inhibition enhances T cell function and sensitizes tumors to immune checkpoint inhibitors.
• Recent Phase 3 trials in prostate cancer combining AR suppression with immune checkpoint blockade failed to show clinical benefit.
• The precise role of AR signaling in modulating anticancer immunity requires further elucidation.

Conclusions:

• Despite promising preclinical data, the combination of AR suppression and immune checkpoint blockade has not translated into clinical benefit in prostate cancer.
• Further research is needed to understand the complex interplay between AR signaling and anticancer immunity.
• Optimized clinical trial designs are necessary to effectively integrate AR suppression strategies with immunotherapy.